Job Watch

HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional)

Funding Opportunity RFA-DA-23-046 from the NIH Guide for Grants and Contracts. This FOA solicits applications for multi-disciplinary RM1 Research Centers (RM1s) that involve partnerships between researchers and payors, health plans, single state agencies/opioid treatment authorities, professional organizations, or other entities. Relevant partners have a deployed or in-development quality measurement and management strategy or system that does or could inform provider or clinician selection and treatment improvement and that rigorous research could substantially advance. Activities should also support the acceptability of the quality measurement and management system to patients, clinicians, and providers; the feasibility, scalability, and sustainability of the system; and equity in quality provider selection and treatment delivery.

NHLBI Announces New Policies Regarding Budget Guidelines for SBIR/STTR Applications

Notice NOT-HL-22-036 from the NIH Guide for Grants and Contracts

NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)

Funding Opportunity RFA-AG-23-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Research and Entrepreneurial Development Immersion (REDI) Small Business Innovation Research (SBIR) Grant applications. The goal of this FOA is to foster the career development of early-career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry. This FOA utilizes the R43/R44 Industry Development Award to provide small business concerns (SBCs) the opportunity to support the hiring and salary of postdoctoral fellows and early-stage researchers as Principal Investigators/Program Directors (PIs/PDs) to increase their scientific research staff and support product development. Additionally, a major component of this FOA is a strong focus on entrepreneurial training, mentoring, and career development of the PD/PI. Postdoctoral fellows and early-career researchers with strong research skills and experience in technology discovery, and that have an interest in growing their entrepreneurial skillset and working in the industry, are optimal PD/PIs for this award.

NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional)

Funding Opportunity RFA-AG-23-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Research and Entrepreneurial Development Immersion (REDI) Small Business Technology Transfer Research (STTR) Grant applications. The goal of this FOA is to foster the career development of early-career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry. This FOA utilizes the R41/R42 Industry Development Award to provide small business concerns (SBCs) the opportunity to support the hiring and salary of postdoctoral fellows and early-stage researchers as Principal Investigators/Program Directors (PIs/PDs) to increase their scientific research staff and support product development. Additionally, a major component of this FOA is a strong focus on entrepreneurial training, mentoring, and career development of the PD/PI. Postdoctoral fellows and early-career researchers with strong research skills and experience in technology discovery, and that have an interest in growing their entrepreneurial skillset and working in the industry, are optimal PD/PIs for this award. Given that the purpose of this FOA is to facilitate the PDs/PIs' transition to the SBC, most of their employment must be at the SBC.

Clinical Variant Scientist - BloodCenter of Wisconsin - Milwaukee, WI

Indeed.com - Bioinformatics - Tue, 2022-07-05 17:10
Experience with bioinformatic analysis and laboratory information systems preferred. Interacts with medical informatics team to maintain and improve sequence…
From Versiti - Tue, 05 Jul 2022 21:10:56 GMT - View all Milwaukee, WI jobs
Categories: Job Watch

Senior Microbiologist - International Flavors & Fragrances - Madison, WI

Indeed.com - Bioinformatics - Tue, 2022-07-05 16:05
Basic knowledge and experience with molecular biology methodologies desirable: nucleic acid manipulation and sequence analysis with an understanding of…
From INTERNATIONAL FLAVORS & FRAGRANCES - Tue, 05 Jul 2022 20:05:03 GMT - View all Madison, WI jobs
Categories: Job Watch

Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)

Funding Opportunity RFA-AG-23-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the Claude D. Pepper Older Americans Independence Centers (OAIC) award. The goal of the OAIC program is to establish centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. OAIC awards are designed to develop or strengthen programs that focus on and sustain progress in a key area in aging research related to the mission of the OAIC program.

Impact of the Microbiome-Gut-Brain Axis on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Not Allowed)

Funding Opportunity PAR-22-211 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for basic and translational research on the impact of the microbiome on Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD). While there is growing evidence that the microbiome is an important factor that contributes to overall health and a variety of diseases and disorders, the role of the alimentary canaland other sources of endogenous microbiota in specific AD/ADRDs has not been adequately addressed. This FOA will support mechanistic research focused on a more rigorous in-depth examination of the potential interactions between the microbiome and genetic and non-genetic molecular targets that influence AD/ADRD. It is expected that these studies will address the clinical relevance of the microbiome on disease initiation, progression, or modification, and will lead ultimately to better therapeutic interventions.

Pages

Subscribe to Anil Jegga aggregator - Job Watch